Physician profile
Esther E Saalfeld
NPI 1407818214
$3,273.24
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $396 · 2021: $601 · 2022: $318 · 2023: $817 · 2024: $52.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.40 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $289.93 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $209.24 | 2019-2023 | |
| Novo Nordisk INC | $207.92 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $193.45 | 2019-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $178.78 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $177.39 | 2019-2022 | |
| Abbott Laboratories | $176.19 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $144.55 | 2019-2023 | Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.43 | 2019-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $126.58 | 2023 | Auvelity |
| Allergan, INC. | $116.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $112.14 | 2019-2021 | |
| Amarin Pharma, INC. | $102.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.63 | 2019-2023 | Jardiance, Tradjenta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $62.91 | 2021 | |
| Lilly USA, LLC | $62.84 | 2019-2023 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $60.75 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.02 | 2023 | |
| Dexcom, INC. | $46.60 | 2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $38.88 | 2019-2022 | |
| Astellas Pharma US INC | $32.16 | 2019-2020 | |
| Almatica Pharma LLC | $28.83 | 2022 | |
| Exact Sciences Corporation | $27.32 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $20.59 | 2022 | |
| Radius Health, INC. | $19.08 | 2019 | |
| Genentech USA, INC. | $18.26 | 2019 | |
| Esperion Therapeutics, INC. | $14.32 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.23 | 2022 | |
| Gilead Sciences, INC. | $11.70 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Saalfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.